Athyrium opportunities iii acquisition lp Biopharma / Nerlynx® July 2021: Aqua Dermatology: Dermatology Provider Group Athyrium Opportunities III Co-Invest 1 SC 13D/A BIORA THERAPEUTICS / Athyrium Opportunities III Co-Invest 1 ownership change. Pricing Other Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; About Athyrium Capital Management Athyrium Capital Management, LP ("Athyrium Capital") is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. 1 . Athyrium Opportunities Iii Acquisition Lp Net Worth 2023 and insider trades. Athyrium Opportunities Associates III LP Athyrium Opportunities Associates III GP LLC 10% Owner: 12,506,250: $0: $0: 62,965,513 (Indirect) View: 2021-06-14 Purchase: 2021-06-14 5:14 pm: PROGENITY INC. V. Mr. Top holders of CareMax Inc sourced from 13F and NPORT filings include: THIS FOURTH AMENDMENT TO CREDIT AGREEMENT AND INVESTMENT DOCUMENTS (this “Agreement”), dated as of November 5, 2020 (the “Fourth Amendment Effective Date”), is entered into among RECRO PHARMA, INC. 13d-1(e), 240. Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Athyrium Funds GP Holdings LLC (Reporting) Athyrium Opportunities 2020 LP (Reporting) Athyrium Opportunities Associates Co-Invest LLC (Reporting) Athyrium Opportunities Associates III GP LLC (Reporting) Athyrium Opportunities Associates III LP (Reporting) Athyrium Opportunities III Acquisition 2 LP (Reporting) Athyrium Opportunities III Acquisition LP Athyrium focuses on investment opportunities in the global healthcare sector broadly defined to include pharmaceuticals, biologics, biotechnology, specialty and generic pharmaceuticals, medical devices and products, laboratory and diagnostics products and services, healthcare services, and healthcare information technology. Assignors: OPTINOSE AS 2019-01-15 Publication of US10179216B2 publication Critical patent/US10179216B2/en 2019-01-15 Application granted granted Critical Athyrium Opportunities III Co-Invest 1 LP (Last) (First) (Middle) 505 FIFTH AVENUE, FLOOR 18 (Street) NEW YORK: NY: 10017 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X: Director: X: 10% Owner: Officer (give title below) Other (specify below) 1. $130,034. (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Note Purchase Agreement dated December 29, 2017, among OptiNose AS and OptiNose US, Inc. , a Pennsylvania corporation (the “Borrower”), the Guarantors (defined herein), the Lenders (defined herein) and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as the Administrative Agent. THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of August 5, 2019 (the “First Amendment Effective Date”), is entered into among DERMIRA, INC. United States Canada UK Hong Kong Japan Australia New Zealand. On August 27, 2019, the Company and Athyrium Opportunities III Acquisition LP (“Acquisition LP”) entered into a Series B Preferred Stock Purchase Agreement pursuant to which Acquisition LP purchased shares of Series B Preferred Stock at $2. Track your favorite companies; Receive email alerts for new filings; Personalized dashboard of Track the AUM, funds, and holdings for Athyrium Opportunities 2020 LP over time. Sen specialized in investments in control and non Discovery Company profile page for Athyrium Opportunities Iii Acquisition 2 LP including technical research,competitor monitor,market trends,company profile& stock symbol. ATHYRIUM OPPORTUNITIES III ACQUISITION LP (LEI# 5493009YUXI1ZQXU5B42) is a legal entity registered with BUSINESS ENTITY DATA B. Biopharma / Nerlynx® July 2021: Aqua Dermatology: Dermatology Provider Group Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Exhibit 10. ☐ ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP, a limited partnership organized under the laws of the State of Delaware having an office at 530 Fifth Avenue, 25th Floor, New York, New York 10036 (“Athyrium”); (3) NORGINE B. This is based on reported shares in BIORA THERAPEUTICS, INC. FIRST AMENDMENT TO CREDIT AGREEMENT . The LEI Track the AUM, funds, and holdings for Athyrium Capital Management LP over time. Private Company. THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of February 19, 2021 (the “Fifth Amendment Effective Date”), is entered into among RECRO PHARMA, INC. The Registered Agent on file for this company is Corporation Service Company and is located at 2711 Centerville Rd Suite 400, Wilmington, DE 19808. The Athyrium Capital team Athyrium Opportunities Associates III LP CIK # 0001815262: EDGAR Form CIK 2011 - 2024; 3 ATHYRIUM OPPORTUNITIES II ACQUISITION LP as of 2024-09-26 ATHYRIUM OPPORTUNITIES II ACQUISITION LP is an active company registered in United States of America. Athyrium Opportunities Fund (B) LP - (a)-(c) & (f) This Schedule 13D is filed jointly by the following persons pursuant to Rule 13d-1(k) promulgated under the Exchange Act: (1) Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership (“Co-Invest LP”), is an investment partnership engaged in the business of making equity and debt investments; (2) Athyrium Opportunities III Acquisition LP, Convertible Senior Secured Notes due 2028, the Company issued to Athyrium Opportunities III Acquisition 2 LP ("Acquisition 2 LP") and Co-Invest LP warrants to purchase 1 10,479 and 346,771 shares of the Company's common stock, par value $0. On August 12, 2024, Biora Therapeutics, Inc. sgml : 20230214 20230214161900 accession number: 0001193125-23-039186 conformed submission type: sc 13g/a public document count: 1 filed as of date: 20230214 date as of change: 20230214 group members: athyrium funds gp holdings llc group members: athyrium opportunities associates iii On April 20, 2020, Progenity, Inc. Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 Sec Form 13D Filing - Athyrium Opportunities 2020 LP filing for BIORA THERAPEUTICS INC - 2023-01-12. CREDIT AGREEMENT . Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a Discovery Company profile page for Athyrium Opportunities Fund III LP including technical research,competitor monitor,market trends,company profile& stock symbol Athyrium Opportunities IV Acquisition 2 LP In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13G with respect to the Ordinary Shares of the Issuer. Com BIORA THERAPEUTICS / Athyrium Opportunities III Co-Invest 1 ownership change, SC 13D/A SEC filing by Biora Therapeutics on 13 Sep 24, 10:37am Athyrium Opportunities IV Acquisition LP as of 2024-08-05 Athyrium Opportunities IV Acquisition LP is an active company registered in United States of America. Acquisition 2 purchased 165,137 shares of Common Stock, and Acquisition LP purchased an aggregate principal amount of $25,000,000 of the 7. : 241210453. Close. Overview. 25% Convertible Notes directly held by Acquisition LP for (1) 2,230,690 shares of the Common Stock, Pre-Funded Warrants to purchase 1,787,209 shares of Common Stock and New York, December 4, 2017 – Athyrium Capital Management, LP (“Athyrium Capital”), a specialized asset management company focused on opportunities in the global healthcare sector, and Neuberger Berman, a global, independent, employee-owned investment manager, are pleased to announce the closing of Athyrium Opportunities Fund III (the “Fund”), which seeks Please be advised that pursuant to the Security Agreement dated as of November 17, 2017 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”) by and among the Grantors party thereto (each a “Grantor” and collectively, the “Grantors”) and Athyrium Opportunities III Acquisition LP, as Administrative Agent (the This page shows a list of all the recent 13D/G filings made by Athyrium Opportunities IV Acquisition 2 LP. on October 28th, 2021 Library English Browse ATHYRIUM OPPORTUNITIES III ACQUISITION LP as of 2024-06-11 ATHYRIUM OPPORTUNITIES III ACQUISITION LP is an active company registered in United States of America. 1. Invest 1 Lp including technical research,competitor monitor,market trends,company profile& stock symbol EXECUTION VERSION . 0 billion of committed capital. FIRST AMENDMENT TO CREDIT AGREEMENT AND INVESTMENT DOCUMENTS . Athyrium is also open to working on a specific transaction alongside a management team by providing acquisition financing towards a particular asset or opportunity. 0: HF: Athyrium Opportunities III Acquisition LP: Ferrell Jeffrey: NB Alternatives Holdings LLC: Athyrium Opportunities III Acquisition LP CIK # 0001835266: EDGAR Form CIK 2011 - 2024; 4 ATHYRIUM OPPORTUNITIES II ACQUISITION 2 LP, a limited partnership whose registered address is at 251 Little Falls Drive Wilmington, DE 19808-1674 (“Athyrium II”); (6) ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP, a limited partnership whose registered address is at 251 Little Falls Drive Wilmington, DE 19808-1674 ( “ Athyrium III ” , and together with Athyrium On December 7, 2020, the Company consummated a follow-on public offering of its Common Stock and a concurrent private placement of its 7. (the "Company"), Athyrium Opportunities III Acquisition LP ("Acquisition LP"), Athyrium Opportunities III Co-Invest 1 LP ("Co-Invest LP") and the other noteholders party thereto entered into a Convertible Notes Exchange Agreement (the "Exchange Agreement") whereby the Company and the holders of In May 2015, Athyrium announced the closing of a successor fund, Athyrium Opportunities Fund II, with over $1. Name and Address of Reporting Person * Athyrium Opportunities III Acquisition LP ATHYRIUM OPPORTUNITIES III ACQUISITION LP Company Number 6049797 Incorporation Date 23 May 2016 (over 6 years ago) Company Type Limited Partnership Jurisdiction Delaware (US) Agent Name CORPORATION SERVICE COMPANY Agent Address 251 LITTLE FALLS DRIVE, WILMINGTON, New Castle, DE, 19808 BIORA THERAPEUTICS / Athyrium Opportunities III Co-Invest 1 ownership change, SC 13D/A SEC filing by Biora Therapeutics on 9 Oct 24, 5:40pm Biom'Up S. Basic Profile Exhibit 10. Athyrium Opportunities Iii Acquisition 2 Lp is incorporated in Delaware and the fiscal year end is in 31 December. It is one of the corporates which submit 10-K filings with the SEC. The company received $9,999,999 from returning investor Athyrium Opportunities III Acquisition 2 LP, a fund managed by Athyrium Capital Discovery Company profile page for Athyrium Opportunities II Co-Invest 1 LP including technical research,competitor monitor,market trends,company profile& stock symbol Explanation of Responses: 1. Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Initial proceeds from this financing, were used to repay and retire the Company’s existing senior secured notes with Athyrium Opportunities III Acquisition LP. THIS FIRST AMENDMENT TO CREDIT AGREEMENT AND INVESTMENT DOCUMENTS (this “Agreem ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP BUSINESS ADDRESS EIN 364883510 An Employer Identification Number (EIN) is also known as a Federal Tax Identification Number, and is used to identify a business entity. Company Marketer / Counterparty Description Initial Investment Date; MedPro Safety Products: Greiner Bio-One: Vacuette Safety System: February 2012: BioFire Diagnostics (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Athyrium Capital Management, LP (“Athyrium Capital”), a specialized asset management company focused on opportunities in the global healthcare sector, and Neuberger Berman, a global, independent, employee-owned investment manager, are pleased to announce the closing of Athyrium Opportunities Fund III (the “Fund”), which seeks to make Company Description Initial Investment Date; Aris Global: HCIT: July 2021: Puma Biotechnology, Inc. SEC Filings include 13F quarterly reports, 13D/G events and more. RELATIONSHIP AGREEMENT Agendia N. Athyrium Opportunities Fund III seeks to make investments of $20 million to $300 million in commercial-stage healthcare companies in North America, Europe, Asia and Track the AUM, funds, and holdings for Athyrium Opportunities III Acquisition LP over time. , a Pennsylvania corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and ATHYRIUM Track the AUM, funds, and holdings for Athyrium Opportunities III Co-Invest 1 LP over time. Home | Sign Up | Log In. The address is C/O Athyrium Capital Detailed Profile of Athyrium Opportunities III Acquisition LP portfolio of holdings. SIXTH AMENDMENT TO CREDIT AGREEMENT. Athyrium Capital manages funds with committed capital in excess of $1. 25% Exhibit 10. JOIN; SI Premium; Ratings; Mergers; Earnings; Dividends Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. BIOR / Biora Therapeutics, Inc. Free signup for more. closed the transaction. The company's File Number is listed as 5980254 . 0 million. Adams joined Athyrium in 2020, and currently serves as Vice President, Senior Counsel. Athyrium Opportunities 2020 LP - Assets, Funds, Holdings. , a Pennsylvania corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto (including in their capacity as holders of the athyrium opportunities iii acquisition 2 lp whitebox relative value partners, lp whitebox gt fund, lp whitebox multi-strategy partners, lp pandora select partners, lp nineteen77 global multi-strategy alpha master limited and nineteen77 global convertible bond THIS SEVENTH AMENDMENT TO CREDIT AGREEMENT AND CONSENT (this “Agreement”), dated as of December 9, 2022 (the “Seventh Amendment Effective Date”), is entered into among Societal CDMO, Inc. This represents 5. 2 percent ownership of the company. Fintel Athyrium Opportunities III Acquisition LP CIK # 0001835266: EDGAR Form CIK 2011 - 2022; 4 Athyrium Opportunities III Acquisition 2 is based out of New York. Sen spent eight years as a senior investment professional and a founding member of the special-situations / distressed group at Littlejohn & Co. , as Parent and a Guarantor, and Athyrium Opportunities III Acquisition LP, as Collateral Agent and a Purchaser Track the AUM, funds, and holdings for Athyrium Opportunities 2020 LP over time. The Borrower has ATHYRIUM OPPORTUNITIES III COMPANY -INVEST 1 LP Schedule 13D/A Filing Concerning BIOR on 2024-09-10 Research. The company's File Number is listed as 6626342 . 13d-l(f) or 240. entered into exclusive negotiations with Athyrium Opportunities III Acquisition LP; a fund managed by Athyrium Capital Management, LP. com (a)-(c) & (f) This Schedule 13D is filed jointly by the following persons pursuant to Rule 13d-1(k) promulgated under the Exchange Act: (1) Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership (“Co-Invest LP”), is an investment partnership engaged in the business of making equity and debt investments; (2) Athyrium Opportunities III Acquisition LP, a Delaware Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Athyrium Opportunities III Acquisition LP does not have any significant net worth to report based on the numbers we have. On July 3, 2024, Biora Therapeutics, Inc. Activist 13D/13G Filings - Athyrium Opportunities III Acquisition 2 LP SecForm4. Business Name ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP 0001193125-24-176464. It is identified by the legal entity identifier (LEI) 549300DJPX8PC2HL2R24. Recent SEC Filings. , a private company with limited liability Athyrium Opportunities IV Acquisition 2 is based out of New York. THIS THIRD AMENDMENT TO CREDIT AGREEMENT AND RELEASE AGREEMENT (this “Agreement”), dated as of October 22, 2019, is entered into among RECRO PHARMA, INC. : 241103240. The address is 505 Fifth Avenue, Floor 18, New York, US-NY, 10017, US. Athyrium Opportunities III Acquisition 2 LP has filed a 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,487,219 shares of CareMax Inc (). This CREDIT AGREEMENT is entered into as of November 17, 2017 among RECRO PHARMA, INC. Compare against similar firms. 2018-02-15 Assigned to ATHYRIUM OPPORTUNITIES III ACQUISITION LP reassignment ATHYRIUM OPPORTUNITIES III ACQUISITION LP SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Log In. Athyrium Opportunities Fund III LP: 255. Whalewisdom has at least 4 13G filings The firm has no submitted 13F filings and does not appear to be an investment advisor. Before joining Athyrium, Mr. In December 2022, Athyrium announced the closing of a Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. Fintel ATHYRIUM OPPORTUNITIES III ACQUISITION LP, a Delaware limited partnership : By: Athyrium Opportunities Associates III LP, its General Partner : By: Athyrium Opportunities Associates III GP LLC, the General Partner of Athyrium Opportunities Associates III LP : By: /s/ Andrew C. View Corporate Tree. txt : 20240708 0001193125-24-176464. 2 billion of committed capital. Athyrium Opportunities III Acquisition 2 LP Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. View the latest funds and 13F holdings. htm EX-10. Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 Track the AUM, funds, and holdings for Athyrium Opportunities Associates LP over time. Patent. and Athyrium Opportunities III Acquisition 2, LP and The Major Shareholders filed by Agendia N. (a)-(c) & (f) This Schedule 13D is filed jointly by the following persons pursuant to Rule 13d-1(k) promulgated under the Exchange Act: (1) Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership (“Co-Invest LP”), is an investment partnership engaged in the business of making equity and debt investments; (2) Athyrium Opportunities III Acquisition LP, a Delaware (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; On September 18, 2023, the Company, Acquisition LP and Co-Invest LP entered into the Exchange Agreement whereby (i) Acquisition LP exchanged $12,077,000 aggregate principal amount of 7. Athyrium Opportunities Associates LP - Assets, Funds, Holdings. Create Alert. sgml : 20240708 20240708214258 ACCESSION NUMBER: 0001193125-24-176464 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUM Explanation of Responses: 1. : 001-39334 | Film No. Pricing Other Shares beneficially owned before this offering consists of 10,929,763 shares of common stock and 14,507,607 shares of common stock issuable upon exercise of warrants and conversion of 2028 Convertible Notes held by Athyrium Opportunities III Acquisition LP (“Acquisition LP”), Athyrium Opportunities III Acquisition 2 LP (“Acquisition 2 LP”), Athyrium Opportunities III Co-Invest 1 LP ATHYRIUM OPPORTUNITIES III ACQUISITION LP, a Delaware limited partnership : By: Athyrium Opportunities Associates III LP, its General Partner : By: Athyrium Opportunities Associates III GP LLC, the General Partner of Athyrium Opportunities Associates III LP : By: /s/ Andrew C. Athyrium recognizes that prolonged financing processes can be very disruptive to management teams. In November 2017, Athyrium announced the closing of a successor fund, Athyrium Opportunities Fund III, with over $2. htm . Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 . txt : 20230214 0001193125-23-039186. Assignors: VELOXIS Athyrium Opportunities Associates III GP LLC CIK # 0001815211: EDGAR Form CIK 2011 - 2023; 3 If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240. 0: 490. ATHYRIUM OPPORTUNITIES II ACQUISITION 2 LP is a Delaware Limited Partnership filed on March 4, 2016. Investment Analyst Sentiment - World. THIS SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of August 13, 2021 (the “Sixth Amendment Effective Date”), is entered into among RECRO PHARMA, INC. Hyman : Title: Authorized Signatory ATHYRIUM OPPORTUNITIES III ACQUISITION LP: By: ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner: By: ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner: By: /s/ Rashida Adams : Name: Rashida Adams : Title: Authorized Signatory: SIGNATURE PAGE TO. Athyrium Opportunities III Acquisition LP: Athyrium Opportunities III Acquisition LP: By: Athyrium Opportunities Associates III LP, its General Partner: By: Athyrium Opportunities Associates III GP LLC, the General Partner of Athyrium Opportunities Associates III LP: By: /s/ Rashida Adams : Name: Rashida Adams : Track the AUM, funds, and holdings for Athyrium Opportunities Associates III LP over time. The address is C/O Athyrium Capital Management, LP, 18th Floor, 505 5th Avenue, New York, US-NY, 10017, US. Capital raising is an exhausting and sometimes frustrating process. Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 Athyrium Opportunities III Acquisition 2 LP sec form 13D/13G filings, stock buying and selling. Track the AUM, funds, and holdings for Athyrium Opportunities II Acquisition LP over time. 01 per share ("common stock"), respectively. FIFTH AMENDMENT TO CREDIT AGREEMENT . ASSIGNMENT OF ASSIGNORS Athyrium Opportunities II Acquisition LP - Activist 13D/13G Filings. , a Pennsylvania corporation (the “Borrower”), the Guarantors party hereto, the Lenders party (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Athyrium Opportunities III Acquisition 2 LP: Athyrium Opportunities Associates III GP LLC: Athyrium Opportunities Associates GP LLC: Track the AUM, funds, and holdings for Athyrium Opportunities Fund (B) LP over time. Athyrium Opportunities III Acquisition LP Top 13F Holdings - WhaleWisdom. (the "Company"), Athyrium Opportunities III Acquisition LP ("Acquisition LP") and Athyrium Opportunities III Co-Invest 1 LP ("Co-Invest LP") entered into a letter agreement pursuant to which, in exchange for Acquisition LP and Co-Invest LP agreeing to forbear from exercising or enforcing certain rights and remedies Who is Athyrium Opportunities IV Acquisition 2 LP? Athyrium Opportunities IV Acquisition 2 LP does not have any significant net worth to report based on the numbers we have. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium Austria Israel Türkiye Track the AUM, funds, and holdings for Athyrium Opportunities Fund (A) LP over time. . Generally, businesses need an EIN. 13d-1(g), check the following box. By submitting this report, Athyrium Opportunities III Acquisition 2 LP is Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“ Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; (4) Athyrium Opportunities 2020 LP, a Delaware limited partnership (“ 2020 LP ATHYRIUM OPPORTUNITIES III ACQUISITION LP (LEI# 5493009YUXI1ZQXU5B42) is a legal entity registered with BUSINESS ENTITY DATA B. About Optinose Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. (f/k/a Recro Pharma, Inc. , a Delaware corporation (the “Borrower”), the LP Portfolios: Related Firms: Build a Portfolio: Comprehensive Search: NB Alternatives GP Holdings LLC CIK # 0001815407: EDGAR Form CIK 2011 - 2024; 3: 4: Form 3/4/5 Subject 2011 - 2024; Athyrium Opportunities III Acquisition LP: Ferrell Jeffrey: NB Alternatives Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. In December 2022, Athyrium announced a final closing for the Athyrium Opportunities Fund IV ("AOF IV" or the "Fund"). : 241553263. Prior to joining Athyrium, Ms. 25% convertible senior notes due 2025 (the “7. 25% Convertible Notes”). Athyrium Opportunities III Acquisition LP: Athyrium Opportunities III Acquisition LP: Ferrell Jeffrey: NB Alternatives Holdings LLC: Athyrium Opportunities Advisers LLC: Biora Therapeutics Inc: Track the AUM, funds, and holdings for Athyrium Opportunities Advisers LLC over time. Athyrium Opportunities II Acquisition LP Portfolio Holdings. Follow. The Registered Agent on file for this company is Corporation Service Company and is located at 251 Little Falls Drive, Wilmington, DE 19808. It is identified by the legal entity identifier (LEI) 5493009YUXI1ZQXU5B42. Fintel ATHYRIUM OPPORTUNITIES III COMPANY -INVEST 1 LP Schedule 13D/A Filing Concerning BIOR on 2024-10-07 Research. : DE | Fiscal Year End: 1231 Type: 4 | Act: 34 | File No. Log-In | Home | E-mail Alerts | My Headlines | Portfolio; Home; Menu. Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 ATHYRIUM OPPORTUNITIES II ACQUISITION 2 LP, a limited partnership whose registered address is at 251 Little Falls Drive Wilmington, DE 19808-1674 (“Athyrium II”); (6) ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP, a limited partnership whose registered address is at 251 Little Falls Drive Wilmington, DE 19808-1674 ( “ Athyrium III ” , and together with Athyrium Detailed Profile of Athyrium Opportunities III Acquisition LP portfolio of holdings. Provides CEO, CFO, Director and Chief Executives trade reports, independent equity Free and open company data on Delaware (US) company ATHYRIUM OPPORTUNITIES III ACQUISITION LP (company number 6049797) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“ Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an (3) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership Athyrium Capital Management, LP (“Athyrium Capital”), a specialized asset management company focused on opportunities in the global healthcare sector, and Neuberger Berman, a ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP is a Delaware Limited Partnership filed on November 21, 2017. Hyman : Title: Authorized Signatory Assignors: ATHYRIUM OPPORTUNITIES III ACQUISITION LP 2020-10-30 Priority to US17/085,379 priority patent/US11123331B2/en 2020-10-30 Priority to US17/085,291 priority patent/US11110081B2/en 2021-03-17 Assigned to VELOXIS PHARMACEUTICALS INC. The Central Index Key (CIK) for Athyrium Opportunities Iii Acquisition 2 Lp is 1815268. PROG: Athyrium Opportunities Fund (A) LP Athyrium Opportunities 2020 LP Athyrium Opportunities III Acquisition 2 LP Athyrium Opportunities III Co Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Athyrium Opportunities III Acquisition 2 LP does not have any significant net worth to report based on the numbers we have. Athyrium Opportunities III Acquisition 2 LP Athyrium Opportunities III Acquisition 2 is based out of New York. Track the AUM, funds, and holdings for Athyrium Opportunities III Acquisition 2 LP over time. The transaction includes participation from Athyrium Opportunities III Acquisition 2 LP, a fund managed by Athyrium Capital Management, LP for 8,097,166 units for proceeds of $20,000,000. ), a Pennsylvania corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and ATHYRIUM OPPORTUNITIES III Athyrium Opportunities III Acquisition 2 LP ("Acquisition 2 LP") pursuant to the terms of the Purchase Agreement, from the Company in exchange for $1,680,000 in, 2. It is identified by the legal entity identifier (LEI) 549300P8ZB6156MXB412. Insider filing report for Changes in Beneficial Ownership. Athyrium Opportunities Advisers LLC - Track the AUM, funds, and holdings for Athyrium Opportunities Associates LP over time. The LEI is a unique co 2017-12-29 Assigned to ATHYRIUM OPPORTUNITIES III ACQUISITION LP reassignment ATHYRIUM OPPORTUNITIES III ACQUISITION LP SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Adams was an associate in the financial restructuring and insolvency group in the New York office of White & Discovery Company profile page for Athyrium Opportunities Iii Co. - BIOR / Biora Therapeutics, Inc. 2. Pricing ATHYRIUM OPPORTUNITIES II ACQUISITION LP (LEI# 549300DJPX8PC2HL2R24) is a legal entity registered with Business Entity Data B. THIRD AMENDMENT TO CREDIT AGREEMENT AND RELEASE AGREEMENT. reassignment VELOXIS PHARMACEUTICALS INC. / Athyrium Opportunities III Co-Invest 1 LP - SC 13D/A Activist Investment - SC 13D/A - September 13, 2024 Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; On June 14, 2021, Progenity, Inc. Free Trial. Toggle navigation open corp data. The Fund has $1,290,000,000 of committed capital. 3. Filed: 13 Sep 24, 10:37am < Back. hdr. Filing Date; SC 13D/A: 2023-11 Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. ATHYRIUM OPPORTUNITIES IV ACQUISITION 2 LP 505 FIFTH AVENUE NEW YORK NY 10017 Business Phone: 212-402-6925. Hyman : Name: Andrew C. , a Pennsylvania corporation (the “Borrower”), the Guarantors party hereto, the Lenders party Athyrium Opportunities III Acquisition 2 LP - Insider Trading Tracker. Schedule 13D is commonly referred to as a “beneficial ownership report. On September 18, 2023, the Company, Acquisition LP and Co-Invest LP entered into the Exchange Agreement whereby (i) Acquisition LP exchanged $12,077,000 aggregate principal amount of 7. EXECUTION VERSION . on October 6th, 2021 Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; Selected news items from Aythrium including press releases from our structured financing investments. and NB Alternatives Advisers LLC for issuance of 6cdf86e516de914bc4dc0a7bd64e3. The LEI 0001193125-23-039186. Athyrium Opportunities Iii Acquisition 2 LP. Exhibit 10. 19 aggregate principal amount has priority under the applicable indenture with regard to cash payments, on December 12, 2024 ef fective as of December 1, 2024 to Athyrium Opportunities III Acquisition LP Athyrium Opportunities III Acquisition 2 LP CIK: 0001815268 (see all company filings) State of Incorp. 25% Convertible Notes directly held by Acquisition LP for (1) 2,230,690 shares of the Common Stock, Pre-Funded Warrants to purchase 1,787,209 shares of Common Stock and ATHYRIUM OPPORTUNITIES III COMPANY -INVEST 1 LP Schedule 13D/A Filing Concerning BIOR on 2024-08-12 Research. The significance of this filing lies in the fact that it indicates the company's commitment to transparency and compliance with regulatory requirements. ” The term "beneficial owner" is defined under SEC rules. A. In a recent SEC filing, Athyrium Opportunities III Acquisition 2 LP (CIK: 0001815268) disclosed important information that investors should take note of. CONVERTIBLE NOTES EXCHANGE Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments; RELATIONSHIP AGREEMENT Agendia N. PCRINwQ494cBL6BHembxgNCyK0ed- EX-10. Funding. Mailing Address 505 FIFTH AVENUE, 18TH FLOOR NEW YORK NY 10017 Company Description Initial Investment Date; Aris Global: HCIT: July 2021: Puma Biotechnology, Inc. Jurisdiction. 75 per share for an aggregate purchase price of $25. Responsive. 1 2 derm-ex101_377. 1 derm-ex101_377. Athyrium Opportunities III Co-Invest 1 LP CIK # 0001815260: EDGAR Form CIK 2011 - 2024; 3 Ms. , as the Issuers, OptiNose, Inc. 7 billion. gpg csxn ejjvbs omopyq daua vqzaoc qpwwjexy swvcv igoy qhkk